1. |
Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol, 2002, 3(11): 655-664.
|
2. |
Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol, 2006, 23(2): 70-83.
|
3. |
Ducimetière F, Lurkin A, Ranchère-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One, 2011, 6(8): e20294. doi: 10.1371/journal.pone.0020294.
|
4. |
Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2022, 33(1): 20-33.
|
5. |
Heinrich MC, Rankin C, Blanke CD, et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 SWOG intergroup trial S0033. JAMA Oncol, 2017, 3(7): 944-952.
|
6. |
Casali PG, Zalcberg J, Le Cesne A, et al. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup phase Ⅲ randomized trial on imatinib at two dose levels. J Clin Oncol, 2017, 35(15): 1713-1720.
|
7. |
Eisenberg BL, Trent JC. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer, 2011, 129(11): 2533-2542.
|
8. |
Rizzo A, Nannini M, Novelli M, et al. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol, 2020, 12: 1758835920936932. doi: 10.1177/1758835920936932.
|
9. |
Mazzocca A, Napolitano A, Silletta M, et al. New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol, 2019, 11: 1758835919841946. doi: 10.1177/1758835919841946.
|
10. |
Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med, 2006, 130(10): 1466-1478.
|
11. |
Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol, 2011, 29(23): 3163-3172.
|
12. |
Onodera T, Goseki N, Kosaki G, et al. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi, 1984, 85(9): 1001-1005.
|
13. |
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010, 17(6): 1471-1474.
|
14. |
中国临床肿瘤学会胃肠间质瘤专家委员会. 中国胃肠间质瘤诊断治疗共识(2017年版). 肿瘤综合治疗电子杂志, 2018, 4(1): 31-43.
|
15. |
DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg, 2000, 231(1): 51-58.
|
16. |
Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7): 472-480.
|
17. |
Raut CP, Espat NJ, Maki RG, et al. Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial. JAMA Oncol, 2018, 4(12): e184060. doi: 10.1001/jamaoncol.2018.4060.
|
18. |
Kim JY, Kim TJ, Lee DK, et al. A preoperative risk prediction model for high malignancy potential gastrointestinal stromal tumors of the stomach. Surg Endosc, 2022, 36(3): 2129-2137.
|
19. |
Li S, Chen D, Li S, et al. Novel prognostic nomogram for recurrence-free survival of patients with primary gastrointestinal stromal tumors after surgical resection: combination of prognostic nutritional index and basic variables. Front Oncol, 2021, 10: 581855. doi: 10.3389/fonc.2020.581855.
|
20. |
Karakas C, Christensen P, Baek D, et al. Dedifferentiated gastrointestinal stromal tumor: recent advances. Ann Diagn Pathol, 2019, 39: 118-124.
|
21. |
Hughes MR, Canals Hernaez D, Cait J, et al. A sticky wicket: Defining molecular functions for CD34 in hematopoietic cells. Exp Hematol, 2020, 86: 1-14.
|
22. |
Alghamdi HM, Amr SS, Shawarby MA, et al. Gastrointestinal stromal tumors. A clinicopathological study. Saudi Med J, 2019, 40(2): 126-130.
|
23. |
李佳鑫, 孙琳, 赵帅, 等. 1 061例胃部与肠道原发胃肠间质瘤的临床病理特征和基因突变特点及预后差异分析. 中华胃肠外科杂志, 2023, 26(4): 346-356.
|
24. |
Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer, 2008, 112(3): 608-615.
|
25. |
Fan X, Han H, Sun Z, et al. Prognostic value of bleeding in gastrointestinal stromal tumors: a meta-analysis. Technol Cancer Res Treat, 2021, 20: 15330338211034259. doi:10.1177/15330338211034259.
|
26. |
Nishida T, Hølmebakk T, Raut CP, et al. Defining tumor rupture in gastrointestinal stromal tumor. Ann Surg Oncol, 2019, 26(6): 1669-1675.
|
27. |
Rutkowski P, Wozniak A, Dębiec-Rychter M, et al. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection. Cancer, 2011, 117(21): 4916-4924.
|
28. |
Bamboat ZM, Dematteo RP. Updates on the management of gastrointestinal stromal tumors. Surg Oncol Clin N Am, 2012, 21(2): 301-316.
|
29. |
Li J, Gong JF, Wu AW, et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol, 2011, 37(4): 319-324.
|
30. |
Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA, 2012, 307(12): 1265-1272.
|
31. |
Joensuu H, Eriksson M, Hall KS, et al. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer, 2014, 120(15): 2325-2333.
|
32. |
Cao X, Cui J, Li Z, et al. Preoperative C-reactive protein/albumin ratio is a prognostic indicator for survival in surgically treated gastrointestinal stromal tumors: a retrospective cohort study. Cancer Manag Res, 2021, 13: 4155-4167.
|
33. |
Van Calster B, Wynants L, Verbeek JFM, et al. Reporting and interpreting decision curve analysis: a guide for investigators. Eur Urol, 2018, 74(6): 796-804.
|